norepinephrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
sympathomimetic, phenethyl derivatives 1960 51-41-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • norepinephrine
  • (R)-Norepinephrine
  • arterenol
  • levarterenol
  • noradrenaline
  • norepinephrine bitartrate
  • (-)-noradrenaline
Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic.
  • Molecular weight: 169.18
  • Formula: C8H11NO3
  • CLOGP: -0.99
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 86.71
  • ALOGS: -1.13
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6 mg P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 3 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 849 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK2,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT1,FLT3,GRK2,GRK3,GSK3B,IGF1R,IKBKB,IRAK1,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MTOR,NTRK1,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,SRC,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 93
kinase-selectivity-class ACVR2B,ACVRL1,AXL,CDK9,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK8,SIK2,STK33,SYK,TEK,TGFBR1 16
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
July 13, 1950 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 599.79 26.08 1099 19647 1383199 89224502
Multiple organ dysfunction syndrome 568.37 26.08 288 20458 68048 90539653
Cardiac arrest 387.02 26.08 261 20485 104674 90503027
Metabolic acidosis 350.48 26.08 195 20551 55481 90552220
Intentional overdose 349.82 26.08 235 20511 93599 90514102
Cardiogenic shock 342.68 26.08 148 20598 24320 90583381
Septic shock 336.01 26.08 220 20526 83940 90523761
Shock 335.33 26.08 153 20593 28625 90579076
Hypotension 278.88 26.08 357 20389 325040 90282661
Acute kidney injury 273.76 26.08 351 20395 320036 90287665
Lactic acidosis 249.16 26.08 151 20595 50312 90557389
Stress cardiomyopathy 248.57 26.08 99 20647 13256 90594445
Acute respiratory distress syndrome 232.63 26.08 119 20627 28567 90579134
Myoglobin urine present 227.50 26.08 49 20697 713 90606988
Hyperlactacidaemia 215.18 26.08 66 20680 4070 90603631
Toxicity to various agents 211.35 26.08 293 20453 287553 90320148
Respiratory failure 201.88 26.08 187 20559 118231 90489470
Peripheral ischaemia 175.27 26.08 61 20685 5606 90602095
Fatigue 174.68 26.08 28 20718 1153995 89453706
Haemodynamic instability 170.85 26.08 73 20673 11666 90596035
Renal failure 164.19 26.08 175 20571 130832 90476869
Bradycardia 163.75 26.08 143 20603 83704 90523997
Electrocardiogram QRS complex prolonged 149.10 26.08 58 20688 7290 90600411
Serotonin syndrome 136.48 26.08 93 20653 37794 90569907
Toxic encephalopathy 136.26 26.08 57 20689 8642 90599059
Pulseless electrical activity 134.80 26.08 57 20689 8875 90598826
Ventricular tachycardia 132.45 26.08 78 20668 24630 90583071
Amylase increased 126.63 26.08 51 20695 7021 90600680
Troponin increased 125.06 26.08 61 20685 13220 90594481
Arthralgia 124.29 26.08 16 20730 778506 89829195
Sepsis 124.26 26.08 178 20568 179636 90428065
Ventricular hypokinesia 122.14 26.08 46 20700 5295 90602406
Tachycardia 120.75 26.08 164 20582 157509 90450192
Headache 119.49 26.08 26 20720 862720 89744981
Hypoxia 118.79 26.08 112 20634 72287 90535414
Acidosis 118.43 26.08 58 20688 12678 90595023
Renal injury 117.80 26.08 54 20692 10189 90597512
Circulatory collapse 113.87 26.08 71 20675 24833 90582868
Extremity necrosis 113.67 26.08 34 20712 1923 90605778
Drug ineffective for unapproved indication 113.00 26.08 105 20641 66539 90541162
Pulmonary oedema 111.47 26.08 101 20645 61979 90545722
Propofol infusion syndrome 107.84 26.08 30 20716 1309 90606392
Overdose 104.38 26.08 153 20593 157556 90450145
Distributive shock 102.59 26.08 36 20710 3388 90604313
Electrocardiogram QT prolonged 101.86 26.08 103 20643 72353 90535348
Premature delivery 100.54 26.08 78 20668 38684 90569017
Disseminated intravascular coagulation 99.98 26.08 62 20684 21476 90586225
Vitamin B1 decreased 97.42 26.08 23 20723 515 90607186
Ventricular fibrillation 96.01 26.08 52 20694 13992 90593709
Dry gangrene 93.27 26.08 23 20723 622 90607079
Pharyngeal haemorrhage 92.89 26.08 23 20723 633 90607068
Blood lactic acid decreased 91.16 26.08 21 20725 421 90607280
Alopecia 89.98 26.08 6 20740 495065 90112636
Nausea 88.41 26.08 75 20671 1110241 89497460
Blood lactate dehydrogenase increased 87.13 26.08 61 20685 25871 90581830
Abdominal discomfort 83.28 26.08 7 20739 477321 90130380
Pruritus 81.95 26.08 13 20733 541512 90066189
Systolic dysfunction 80.75 26.08 26 20720 1878 90605823
Nasopharyngitis 80.08 26.08 3 20743 407101 90200600
Cardiac output increased 76.90 26.08 19 20727 518 90607183
Blood creatine phosphokinase increased 76.56 26.08 63 20683 33960 90573741
Renal impairment 75.16 26.08 106 20640 105315 90502386
Rash 74.76 26.08 45 20701 796055 89811646
Suicide attempt 74.37 26.08 89 20657 75310 90532391
Weight increased 73.25 26.08 6 20740 417921 90189780
Blood potassium increased 72.50 26.08 50 20696 20699 90587002
Anuria 72.19 26.08 44 20702 14774 90592927
Coagulopathy 71.82 26.08 52 20694 23237 90584464
Activated partial thromboplastin time prolonged 70.85 26.08 35 20711 7790 90599911
Vasoplegia syndrome 70.81 26.08 26 20720 2788 90604913
Left ventricle outflow tract obstruction 70.60 26.08 17 20729 415 90607286
Infusion related reaction 70.31 26.08 7 20739 416773 90190928
Cardiomyopathy 68.97 26.08 48 20698 20158 90587543
Hypersensitivity 68.57 26.08 11 20735 454666 90153035
Atrioventricular block first degree 68.07 26.08 35 20711 8476 90599225
Pain in extremity 67.72 26.08 11 20735 450518 90157183
Fall 67.62 26.08 14 20732 481796 90125905
Alanine aminotransferase increased 65.86 26.08 106 20640 118232 90489469
Electrocardiogram ST segment elevation 65.20 26.08 27 20719 3989 90603712
Fear 65.11 26.08 43 20703 16579 90591122
Pain 64.80 26.08 80 20666 996261 89611440
Cardio-respiratory arrest 64.69 26.08 76 20670 63064 90544637
Coma 62.41 26.08 80 20666 72552 90535149
Pemphigus 62.30 26.08 3 20743 326861 90280840
Patent ductus arteriosus 61.84 26.08 27 20719 4542 90603159
Weight decreased 60.03 26.08 8 20738 379902 90227799
Hypoaesthesia 59.51 26.08 3 20743 314207 90293494
Systemic lupus erythematosus 58.68 26.08 7 20739 361889 90245812
Wrong product administered 56.94 26.08 30 20716 7635 90600066
Diabetes insipidus 56.94 26.08 23 20723 3189 90604512
Hyperkalaemia 56.51 26.08 72 20674 64892 90542809
Compartment syndrome 55.60 26.08 22 20724 2890 90604811
Oliguria 55.51 26.08 33 20713 10591 90597110
Malaise 55.11 26.08 33 20713 585953 90021748
Dizziness 54.29 26.08 34 20712 589250 90018451
Blood phosphorus increased 53.55 26.08 24 20722 4294 90603407
Swelling 53.25 26.08 15 20731 419043 90188658
Insomnia 52.73 26.08 7 20739 333467 90274234
Diarrhoea 52.47 26.08 84 20662 939106 89668595
Contraindicated product administered 52.38 26.08 6 20740 320133 90287568
Peripheral swelling 52.10 26.08 15 20731 413091 90194610
Reversible cerebral vasoconstriction syndrome 51.37 26.08 23 20723 4107 90603594
Cardiotoxicity 50.87 26.08 32 20714 11357 90596344
Stomatitis 50.84 26.08 3 20743 274695 90333006
Respiratory depression 50.83 26.08 36 20710 15539 90592162
Vitamin B1 increased 50.50 26.08 11 20735 169 90607532
Ventricular arrhythmia 50.37 26.08 23 20723 4298 90603403
Electrocardiogram ST segment depression 49.57 26.08 21 20725 3282 90604419
Ischaemic hepatitis 49.51 26.08 20 20726 2773 90604928
Analgesic therapy 49.31 26.08 14 20732 658 90607043
Product dose omission issue 48.90 26.08 5 20741 291682 90316019
Heparin-induced thrombocytopenia 48.81 26.08 24 20722 5288 90602413
Electrocardiogram abnormal 48.69 26.08 30 20716 10268 90597433
Hypothermia 48.53 26.08 35 20711 15540 90592161
Drug intolerance 48.34 26.08 21 20725 447570 90160131
Antacid therapy 47.72 26.08 14 20732 740 90606961
Appendicolith 47.59 26.08 14 20732 747 90606954
Musculoskeletal stiffness 47.42 26.08 6 20740 296526 90311175
Drug therapy 46.75 26.08 14 20732 795 90606906
Drug hypersensitivity 46.61 26.08 24 20722 463585 90144116
Anticoagulant therapy 46.61 26.08 14 20732 803 90606898
Drug interaction 46.44 26.08 154 20592 276299 90331402
Therapeutic product effect decreased 45.91 26.08 5 20741 277566 90330135
Anhedonia 45.81 26.08 30 20716 11401 90596300
Brain death 45.61 26.08 21 20725 4000 90603701
Acute generalised exanthematous pustulosis 45.48 26.08 32 20714 13671 90594030
Premature baby 45.38 26.08 41 20705 25036 90582665
Leukocytosis 45.26 26.08 45 20701 30945 90576756
Mydriasis 45.11 26.08 33 20713 14979 90592722
Gait disturbance 44.90 26.08 4 20742 260492 90347209
Acid base balance abnormal 42.92 26.08 11 20735 349 90607352
Back pain 42.88 26.08 10 20736 317165 90290536
Torsade de pointes 42.54 26.08 32 20714 15150 90592551
Intestinal ischaemia 42.31 26.08 26 20720 8857 90598844
Abdominal pain upper 42.08 26.08 12 20734 332662 90275039
Decreased appetite 41.71 26.08 17 20729 376523 90231178
Vasoconstriction 41.31 26.08 13 20733 872 90606829
Foetal exposure during pregnancy 41.17 26.08 50 20696 42925 90564776
Blood pressure decreased 40.17 26.08 66 20680 74829 90532872
Encephalopathy 39.64 26.08 51 20695 46393 90561308
Sinus bradycardia 39.41 26.08 32 20714 16920 90590781
Anion gap increased 39.36 26.08 16 20730 2254 90605447
Thrombocytopenia 39.34 26.08 121 20625 208604 90399097
Respiratory acidosis 39.27 26.08 24 20722 8095 90599606
Sinus tachycardia 39.07 26.08 40 20706 28473 90579228
Depressed level of consciousness 38.85 26.08 64 20682 72720 90534981
Rhabdomyolysis 38.69 26.08 53 20693 51203 90556498
Unmasking of previously unidentified disease 38.48 26.08 14 20732 1462 90606239
Urticaria 38.24 26.08 12 20734 312722 90294979
Contusion 38.01 26.08 6 20740 251210 90356491
Paraesthesia 37.83 26.08 6 20740 250320 90357381
Infection 37.50 26.08 18 20728 362076 90245625
Hepatic enzyme increased 37.26 26.08 18 20728 360718 90246983
Maternal exposure during delivery 37.21 26.08 18 20728 3828 90603873
Diabetic macroangiopathy 36.60 26.08 8 20738 125 90607576
Product use issue 36.37 26.08 15 20731 329904 90277797
Unevaluable event 35.92 26.08 53 20693 54795 90552906
Haemolysis 35.74 26.08 23 20723 8487 90599214
Lower respiratory tract infection 35.71 26.08 7 20739 250652 90357049
Pulmonary hypertensive crisis 35.28 26.08 10 20736 467 90607234
Blood creatinine increased 35.08 26.08 74 20672 101312 90506389
Acute lung injury 34.61 26.08 13 20733 1485 90606216
Myocardial stunning 34.57 26.08 9 20737 304 90607397
Myoglobin blood increased 34.16 26.08 13 20733 1539 90606162
Asthma 34.01 26.08 7 20739 242153 90365548
Necrosis 33.15 26.08 20 20726 6590 90601111
Seizure 33.07 26.08 93 20653 152536 90455165
Renal tubular necrosis 32.84 26.08 27 20719 14528 90593173
Bronchopulmonary dysplasia 32.63 26.08 10 20736 614 90607087
Brain oedema 32.59 26.08 29 20717 17356 90590345
Electrocardiogram repolarisation abnormality 32 26.08 12 20734 1364 90606337
Muscle spasms 32 26.08 9 20737 251874 90355827
Hyperphosphataemia 31.83 26.08 16 20730 3695 90604006
Memory impairment 31.50 26.08 4 20742 197240 90410461
Neurodevelopmental disorder 31.49 26.08 8 20738 245 90607456
Off label use 31.29 26.08 387 20359 1101865 89505836
Wheezing 31.20 26.08 8 20738 238072 90369629
Muscular weakness 31.12 26.08 5 20741 206661 90401040
Acute coronary syndrome 30.76 26.08 23 20723 10790 90596911
Respiratory distress 30.50 26.08 41 20705 38905 90568796
Bundle branch block left 29.92 26.08 20 20726 7865 90599836
Arteriospasm coronary 29.86 26.08 17 20729 5033 90602668
Hypotonia 29.63 26.08 23 20723 11403 90596298
Altered state of consciousness 29.09 26.08 36 20710 31496 90576205
Injection site pain 29.04 26.08 3 20743 173696 90434005
Mental status changes 29.01 26.08 43 20703 44636 90563065
Acute respiratory failure 28.87 26.08 42 20704 42876 90564825
Ventricular extrasystoles 28.69 26.08 24 20722 13226 90594475
Treatment failure 28.68 26.08 17 20729 303911 90303790
Foetal exposure during delivery 28.26 26.08 8 20738 372 90607329
Right ventricular failure 28.25 26.08 28 20718 19177 90588524
Toxic epidermal necrolysis 28.20 26.08 36 20710 32492 90575209
Depression 28.11 26.08 17 20729 300584 90307117
Device related sepsis 27.98 26.08 16 20730 4777 90602924
Hyperglycaemia 27.44 26.08 45 20701 50925 90556776
Sleep disorder 27.24 26.08 6 20740 198024 90409677
Systolic anterior motion of mitral valve 26.65 26.08 5 20741 34 90607667
Aspartate aminotransferase increased 26.62 26.08 67 20679 102870 90504831
Cardiovascular insufficiency 26.56 26.08 11 20735 1624 90606077
Vasodilatation 26.41 26.08 13 20733 2871 90604830
Emotional distress 26.31 26.08 37 20709 36625 90571076
Apallic syndrome 26.28 26.08 9 20737 787 90606914
Gastrointestinal disorder 26.20 26.08 13 20733 256674 90351027

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 680.80 21.23 546 28258 96489 42496042
Drug ineffective 616.80 21.23 1323 27481 628874 41963657
Cardiogenic shock 484.59 21.23 301 28503 35339 42557192
Appendicolith 424.78 21.23 199 28605 13257 42579274
Appendicitis 358.10 21.23 204 28600 20409 42572122
Ventricular fibrillation 289.41 21.23 205 28599 29918 42562613
Septic shock 222.03 21.23 291 28513 91381 42501150
Blood phosphorus increased 217.56 21.23 124 28680 12401 42580130
Ascites 214.07 21.23 226 28578 56452 42536079
Sepsis 194.87 21.23 421 28383 198913 42393618
Myasthenia gravis 191.01 21.23 125 28679 16012 42576519
Hyperphosphataemia 179.48 21.23 111 28693 12893 42579638
Cardiac arrest 178.51 21.23 288 28516 109032 42483499
Abdominal distension 169.39 21.23 225 28579 71510 42521021
Toxic epidermal necrolysis 169.03 21.23 142 28662 26608 42565923
Propofol infusion syndrome 169.00 21.23 53 28751 1156 42591375
Shock 164.54 21.23 145 28659 28976 42563555
Analgesic therapy 150.60 21.23 78 28726 6446 42586085
Diarrhoea 150.46 21.23 62 28742 460787 42131744
Sleep disorder therapy 143.74 21.23 77 28727 6817 42585714
Hypophosphataemia 142.35 21.23 116 28688 20829 42571702
Hypotension 140.47 21.23 437 28367 257194 42335337
Drug therapy 137.92 21.23 73 28731 6307 42586224
Bacterial infection 134.38 21.23 127 28677 27752 42564779
Fatigue 133.67 21.23 64 28740 435577 42156954
Hyponatraemia 131.01 21.23 241 28563 101221 42491310
Activated partial thromboplastin time prolonged 127.28 21.23 97 28707 15806 42576725
Weight decreased 126.32 21.23 3 28801 207945 42384586
Blood uric acid increased 124.81 21.23 95 28709 15452 42577079
Incorrect route of product administration 119.59 21.23 112 28692 24193 42568338
Respiratory failure 118.55 21.23 265 28539 127867 42464664
Arthralgia 117.40 21.23 5 28799 205233 42387298
Fear 108.41 21.23 76 28728 10889 42581642
Neuralgia 107.07 21.23 108 28696 25539 42566992
Acute kidney injury 106.64 21.23 510 28294 366827 42225704
Dizziness 106.22 21.23 20 28784 249234 42343297
Fall 106.16 21.23 16 28788 234504 42358027
Condition aggravated 104.99 21.23 400 28404 260354 42332177
Stress 104.77 21.23 139 28665 44073 42548458
Haemodynamic instability 103.60 21.23 78 28726 12479 42580052
Blood cholesterol increased 101.51 21.23 107 28697 26634 42565897
Iron deficiency 100.91 21.23 73 28731 10988 42581543
Antacid therapy 99.21 21.23 53 28751 4664 42587867
Metabolic acidosis 97.59 21.23 146 28658 51712 42540819
Off label use 92.95 21.23 741 28063 637594 41954937
Anticoagulant therapy 92.71 21.23 50 28754 4485 42588046
General physical health deterioration 90.13 21.23 265 28539 150981 42441550
Pruritus 89.85 21.23 11 28793 188760 42403771
Rhabdomyolysis 87.93 21.23 175 28629 77844 42514687
Acute respiratory distress syndrome 87.78 21.23 105 28699 30003 42562528
Dry mouth 86.32 21.23 120 28684 39759 42552772
Vasoplegia syndrome 85.99 21.23 40 28764 2615 42589916
Lactic acidosis 85.98 21.23 128 28676 45133 42547398
Pain in extremity 85 21.23 4 28800 150600 42441931
Renal injury 83.39 21.23 68 28736 12212 42580319
Renal failure 81.05 21.23 247 28557 143479 42449052
Rash 78.38 21.23 45 28759 276909 42315622
Coma 77.76 21.23 134 28670 53420 42539111
Anhedonia 75.63 21.23 53 28751 7587 42584944
Injury 75.42 21.23 84 28720 22232 42570299
Malaise 74.96 21.23 25 28779 212131 42380400
Decreased appetite 73.22 21.23 20 28784 193117 42399414
Blood calcium increased 68.59 21.23 52 28752 8402 42584129
Mechanical ventilation complication 66.69 21.23 23 28781 681 42591850
Intestinal ischaemia 65.89 21.23 53 28751 9335 42583196
Peripheral ischaemia 64.22 21.23 45 28759 6440 42586091
End stage renal disease 64.15 21.23 67 28737 16491 42576040
Congenital hiatus hernia 63.85 21.23 44 28760 6130 42586401
Bradycardia 63 21.23 162 28642 85322 42507209
Bronchopulmonary aspergillosis allergic 62.79 21.23 39 28765 4559 42587972
Emotional distress 62.14 21.23 65 28739 16028 42576503
Headache 62.04 21.23 43 28761 239326 42353205
Dry gangrene 61.69 21.23 20 28784 487 42592044
Asthenia 60.97 21.23 60 28744 280733 42311798
Diabetes insipidus 59.77 21.23 35 28769 3678 42588853
Drug ineffective for unapproved indication 58.66 21.23 109 28695 46054 42546477
Ventricular tachycardia 56.83 21.23 85 28719 30075 42562456
Drug reaction with eosinophilia and systemic symptoms 56.82 21.23 102 28702 41973 42550558
Ulcer 55.75 21.23 62 28742 16379 42576152
Weight increased 54.65 21.23 5 28799 107978 42484553
Swelling 53.46 21.23 116 28688 54769 42537762
Cough 53.16 21.23 27 28777 178076 42414455
Diabetes mellitus 51.83 21.23 121 28683 59966 42532565
Blood test abnormal 51.39 21.23 53 28751 12853 42579678
Gait disturbance 51.07 21.23 4 28800 97996 42494535
Thrombosis 50.63 21.23 130 28674 68381 42524150
Total lung capacity decreased 50.58 21.23 31 28773 3539 42588992
Acidosis 49.94 21.23 51 28753 12228 42580303
Electrocardiogram QRS complex prolonged 49.87 21.23 37 28767 5786 42586745
Dehydration 49.52 21.23 17 28787 141750 42450781
Stress cardiomyopathy 49.49 21.23 28 28776 2757 42589774
Myocardial calcification 49.41 21.23 10 28794 29 42592502
Insomnia 49.22 21.23 10 28794 118243 42474288
Haemothorax 48.76 21.23 35 28769 5201 42587330
Anion gap 48.43 21.23 19 28785 814 42591717
Chest pain 48.28 21.23 17 28787 139513 42453018
Troponin increased 46.78 21.23 61 28743 19001 42573530
Methaemoglobinaemia 45.70 21.23 35 28769 5739 42586792
Nasopharyngitis 45.00 21.23 3 28801 83993 42508538
Pulseless electrical activity 43.65 21.23 40 28764 8397 42584134
Bacteroides infection 43.26 21.23 25 28779 2562 42589969
Lung opacity 43.20 21.23 34 28770 5803 42586728
Aortic stenosis 42.42 21.23 40 28764 8705 42583826
Heparin-induced thrombocytopenia 41.60 21.23 35 28769 6562 42585969
Anaphylactic shock 41.09 21.23 64 28740 23453 42569078
Hyperlipidaemia 41.05 21.23 61 28743 21455 42571076
Burkholderia test positive 40.92 21.23 18 28786 1032 42591499
Product use in unapproved indication 40.80 21.23 238 28566 184218 42408313
Sleep disorder 40.54 21.23 96 28708 47999 42544532
Unevaluable event 39.90 21.23 78 28726 34210 42558321
Pleuritic pain 39.46 21.23 35 28769 7042 42585489
Abdominal discomfort 39.41 21.23 3 28801 75252 42517279
Electrocardiogram T wave alternans 39.00 21.23 10 28794 101 42592430
Aspiration 38.95 21.23 54 28750 17832 42574699
Pharyngeal haemorrhage 38.67 21.23 16 28788 788 42591743
Neutropenia 38.40 21.23 47 28757 199384 42393147
Shock haemorrhagic 38.34 21.23 51 28753 16191 42576340
Malignant neoplasm progression 37.84 21.23 13 28791 108387 42484144
Hyperdynamic left ventricle 37.82 21.23 12 28792 272 42592259
Drug abuse 37.57 21.23 12 28792 104759 42487772
Liver function test increased 37.15 21.23 56 28748 19942 42572589
Hypoaesthesia 37.00 21.23 3 28801 71460 42521071
Chronic obstructive pulmonary disease 36.94 21.23 110 28694 63004 42529527
Feeling abnormal 35.93 21.23 3 28801 69783 42522748
Arteriospasm coronary 35.93 21.23 28 28776 4710 42587821
Dyspnoea 35.68 21.23 166 28638 442455 42150076
Abdominal pain 35.37 21.23 235 28569 190236 42402295
Compartment syndrome 35.33 21.23 24 28780 3265 42589266
Gout 35.32 21.23 66 28738 27989 42564542
Inspiratory capacity decreased 35.13 21.23 23 28781 2944 42589587
Confusional state 34.97 21.23 37 28767 167560 42424971
Disseminated intravascular coagulation 34.61 21.23 61 28743 24733 42567798
Electrocardiogram QT prolonged 34.40 21.23 90 28714 47855 42544676
Constipation 34.32 21.23 207 28597 162084 42430447
Transaminases increased 33.73 21.23 71 28733 32814 42559717
Back pain 33.45 21.23 28 28776 141748 42450783
Paraesthesia 33.20 21.23 5 28799 73454 42519077
Hyperhidrosis 33.10 21.23 10 28794 90502 42502029
Syncope 32.88 21.23 13 28791 99393 42493138
Drug hypersensitivity 32.33 21.23 143 28661 99246 42493285
Coagulopathy 31.55 21.23 55 28749 22107 42570424
Distributive shock 31.15 21.23 20 28784 2476 42590055
Systemic candida 31.05 21.23 27 28777 5292 42587239
Overdose 30.21 21.23 146 28658 105118 42487413
Interstitial lung disease 29.93 21.23 8 28796 78454 42514077
Myalgia 29.50 21.23 14 28790 96066 42496465
Oliguria 27.99 21.23 33 28771 9280 42583251
Chest discomfort 27.26 21.23 5 28799 63611 42528920
Adverse reaction 26.87 21.23 22 28782 3971 42588560
Influenza 26.40 21.23 5 28799 62170 42530361
Ischaemia 26.25 21.23 24 28780 5023 42587508
Locked-in syndrome 26.21 21.23 10 28794 397 42592134
Somnolence 26.11 21.23 174 28630 140931 42451600
Product dose omission issue 26.05 21.23 40 28764 154325 42438206
Micturition urgency 26.02 21.23 36 28768 11862 42580669
Cholestasis 25.96 21.23 64 28740 32815 42559716
Left ventricle outflow tract obstruction 25.52 21.23 8 28796 174 42592357
Abdominal pain upper 25.41 21.23 12 28792 82597 42509934
Pulse absent 25.22 21.23 26 28778 6301 42586230
Extremity necrosis 25.10 21.23 17 28787 2302 42590229
Erythema 25.03 21.23 22 28782 108771 42483760
Hypertransaminasaemia 24.96 21.23 31 28773 9196 42583335
Angiopathy 24.95 21.23 24 28780 5353 42587178
Angle closure glaucoma 24.70 21.23 13 28791 1109 42591422
Tachycardia 24.67 21.23 134 28670 100953 42491578
White blood cell count decreased 24.59 21.23 23 28781 110373 42482158
Muscular weakness 24.38 21.23 13 28791 83485 42509046
Laryngomalacia 24.29 21.23 9 28795 329 42592202
Inappropriate schedule of product administration 23.79 21.23 18 28786 95884 42496647
Pulmonary embolism 23.65 21.23 150 28654 119462 42473069
Dyspnoea exertional 23.63 21.23 3 28801 50145 42542386
Cholangiolitis 23.27 21.23 5 28799 21 42592510
Respiratory depression 23.27 21.23 44 28760 18824 42573707
Hyperthermia malignant 23.01 21.23 17 28787 2641 42589890
Intentional overdose 22.30 21.23 81 28723 51375 42541156
Blood glucose increased 22.22 21.23 11 28793 73688 42518843
Myocardial infarction 22.03 21.23 31 28773 123978 42468553
Infection 21.98 21.23 26 28778 112042 42480489
Drug intolerance 21.96 21.23 110 28694 80314 42512217
Symmetrical drug-related intertriginous and flexural exanthema 21.83 21.23 11 28793 857 42591674
Bronchitis 21.82 21.23 3 28801 47198 42545333
Dysphagia 21.70 21.23 11 28793 72708 42519823
Completed suicide 21.60 21.23 20 28784 96445 42496086
Splenic abscess 21.58 21.23 10 28794 648 42591883
Stomatitis 21.47 21.23 4 28800 50325 42542206
Hypercapnia 21.31 21.23 22 28782 5339 42587192

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 1303.03 23.12 2322 45275 1518218 109023484
Multiple organ dysfunction syndrome 1237.88 23.12 785 46812 150925 110390777
Cardiogenic shock 839.66 23.12 435 47162 56903 110484799
Appendicolith 549.15 23.12 213 47384 14042 110527660
Septic shock 534.97 23.12 483 47114 157045 110384657
Cardiac arrest 519.59 23.12 525 47072 196228 110345474
Shock 445.29 23.12 281 47316 53307 110488395
Ventricular fibrillation 434.49 23.12 252 47345 41061 110500641
Appendicitis 425.18 23.12 219 47378 28245 110513457
Metabolic acidosis 378.69 23.12 326 47271 99418 110442284
Hypotension 372.57 23.12 744 46853 523105 110018597
Sepsis 355.53 23.12 560 47037 326786 110214916
Acute kidney injury 312.62 23.12 779 46818 634651 109907051
Blood phosphorus increased 310.15 23.12 148 47449 16192 110525510
Respiratory failure 305.45 23.12 418 47179 214914 110326788
Fatigue 293.29 23.12 81 47516 1215877 109325825
Intentional overdose 289.69 23.12 320 47277 132181 110409521
Lactic acidosis 280.72 23.12 267 47330 92544 110449158
Acute respiratory distress syndrome 278.65 23.12 210 47387 52988 110488714
Propofol infusion syndrome 271.66 23.12 82 47515 2507 110539195
Haemodynamic instability 260.37 23.12 147 47450 22741 110518961
Arthralgia 257.40 23.12 21 47576 779611 109762091
Ascites 254.44 23.12 253 47344 92555 110449147
Stress cardiomyopathy 248.74 23.12 126 47471 15680 110526022
Hyperphosphataemia 247.37 23.12 127 47470 16254 110525448
Renal failure 240.70 23.12 384 47213 226190 110315512
Analgesic therapy 225.49 23.12 93 47504 7191 110534511
Myasthenia gravis 222.88 23.12 130 47467 21381 110520321
Activated partial thromboplastin time prolonged 220.77 23.12 131 47466 22237 110519465
Drug therapy 208.58 23.12 88 47509 7203 110534499
Bradycardia 208.56 23.12 294 47303 155223 110386479
Peripheral ischaemia 200.27 23.12 97 47500 10961 110530741
Headache 197.57 23.12 67 47530 882310 109659392
Diarrhoea 193.24 23.12 127 47470 1139378 109402324
Sleep disorder therapy 190.10 23.12 83 47514 7388 110534314
Ventricular tachycardia 184.70 23.12 161 47436 49848 110491854
Toxic epidermal necrolysis 182.60 23.12 169 47428 56558 110485144
Renal injury 177.93 23.12 107 47490 18606 110523096
Blood uric acid increased 174.01 23.12 111 47486 21418 110520284
Pruritus 172.94 23.12 23 47574 581537 109960165
Electrocardiogram QRS complex prolonged 171.12 23.12 92 47505 12929 110528773
Fall 169.93 23.12 28 47569 603454 109938248
Drug ineffective for unapproved indication 169.38 23.12 215 47382 102623 110439079
Myoglobin urine present 168.41 23.12 45 47552 875 110540827
Weight decreased 161.81 23.12 10 47587 468047 110073655
Hyperlactacidaemia 160.12 23.12 76 47521 8210 110533492
Vasoplegia syndrome 160.11 23.12 67 47530 5372 110536330
Antacid therapy 159.58 23.12 67 47530 5417 110536285
Hypophosphataemia 158.41 23.12 124 47473 33058 110508644
Pain in extremity 158.17 23.12 14 47583 487104 110054598
Dizziness 157.93 23.12 52 47545 698141 109843561
Dry gangrene 157.35 23.12 44 47553 1020 110540682
Pulseless electrical activity 154.64 23.12 94 47503 16663 110525039
Rhabdomyolysis 154.57 23.12 223 47374 120178 110421524
Malaise 153.78 23.12 49 47548 671770 109869932
Bacterial infection 153.70 23.12 140 47457 45896 110495806
Troponin increased 152.50 23.12 116 47481 29650 110512052
Anticoagulant therapy 151.01 23.12 64 47533 5297 110536405
Rash 149.43 23.12 84 47513 820880 109720822
Fear 145.14 23.12 102 47495 23091 110518611
Nasopharyngitis 143.96 23.12 6 47591 394355 110147347
Coma 143.61 23.12 213 47384 117656 110424046
Weight increased 141.98 23.12 10 47587 419634 110122068
Off label use 137.20 23.12 1106 46491 1499079 109042623
Abdominal discomfort 134.36 23.12 9 47588 393849 110147853
Toxicity to various agents 132.58 23.12 481 47116 480074 110061628
Hyponatraemia 129.53 23.12 288 47309 217365 110324337
Alopecia 128.45 23.12 7 47590 364746 110176956
Electrocardiogram QT prolonged 127.17 23.12 193 47404 108767 110432935
Acidosis 122.52 23.12 91 47506 22440 110519262
Tachycardia 119.56 23.12 286 47311 226359 110315343
Abdominal distension 119.51 23.12 245 47352 174858 110366844
Peripheral swelling 117.62 23.12 17 47580 404017 110137685
Intestinal ischaemia 117.47 23.12 78 47519 16101 110525601
Diabetes insipidus 117.06 23.12 57 47540 6513 110535189
Pharyngeal haemorrhage 115.78 23.12 37 47560 1370 110540332
Disseminated intravascular coagulation 115.76 23.12 114 47483 41172 110500530
Overdose 114.79 23.12 287 47310 233507 110308195
Serotonin syndrome 114.13 23.12 134 47463 59019 110482683
Hypoaesthesia 110.72 23.12 6 47591 314217 110227485
Distributive shock 110.57 23.12 53 47544 5851 110535851
Iron deficiency 110.39 23.12 79 47518 18397 110523305
Sinusitis 110 23.12 4 47593 296684 110245018
Extremity necrosis 109.12 23.12 46 47551 3756 110537946
Anhedonia 108.69 23.12 73 47524 15355 110526347
Decreased appetite 108.27 23.12 35 47562 475811 110065891
Infusion related reaction 106.50 23.12 18 47579 381144 110160558
End stage renal disease 106.30 23.12 82 47515 21391 110520311
Condition aggravated 105.89 23.12 607 46990 734229 109807473
Insomnia 103.05 23.12 16 47581 360574 110181128
Neuralgia 100.54 23.12 114 47483 48364 110493338
Circulatory collapse 99.36 23.12 107 47490 42886 110498816
Incorrect route of product administration 97.73 23.12 129 47468 63932 110477770
Stomatitis 92.65 23.12 6 47591 270236 110271466
Stress 91.05 23.12 163 47434 105185 110436517
Gait disturbance 90.22 23.12 8 47589 278200 110263502
Heparin-induced thrombocytopenia 90.08 23.12 58 47539 11366 110530336
Coagulopathy 89.63 23.12 99 47498 40812 110500890
Renal impairment 87.96 23.12 227 47370 188218 110353484
Wound 87.46 23.12 3 47594 234434 110307268
Left ventricle outflow tract obstruction 87.40 23.12 24 47573 519 110541183
Compartment syndrome 86.85 23.12 45 47552 5865 110535837
Abdominal pain upper 86.16 23.12 22 47575 349089 110192613
Pulmonary oedema 86.04 23.12 155 47442 100504 110441198
Drug reaction with eosinophilia and systemic symptoms 85.46 23.12 138 47459 81957 110459745
Mobility decreased 85.33 23.12 4 47593 237418 110304284
Muscle spasms 85.02 23.12 10 47587 278147 110263555
Congenital hiatus hernia 84.42 23.12 45 47552 6214 110535488
Paraesthesia 84.37 23.12 10 47587 276511 110265191
Oliguria 83.21 23.12 67 47530 18590 110523112
Blood calcium increased 83.05 23.12 66 47531 17974 110523728
Discomfort 79.21 23.12 3 47594 214704 110326998
Pemphigus 79.15 23.12 3 47594 214567 110327135
Mechanical ventilation complication 79.09 23.12 24 47573 747 110540955
Hypoxia 78.82 23.12 173 47424 129342 110412360
Electrocardiogram ST segment elevation 78.45 23.12 49 47548 9111 110532591
Systemic lupus erythematosus 78.09 23.12 9 47588 254329 110287373
Pain 78.07 23.12 186 47411 954769 109586933
Unevaluable event 77.87 23.12 111 47486 59116 110482586
Blood lactic acid decreased 76.49 23.12 22 47575 566 110541136
Anuria 75.38 23.12 71 47526 24270 110517432
Toxic encephalopathy 75.09 23.12 58 47539 15156 110526546
Therapeutic product effect decreased 74.13 23.12 9 47588 244307 110297395
Ventricular hypokinesia 74.09 23.12 51 47546 11163 110530539
Asthenia 73.91 23.12 114 47483 688885 109852817
Cough 73.26 23.12 55 47542 461586 110080116
Contusion 72.29 23.12 8 47589 233353 110308349
Hyperlipidaemia 72.13 23.12 83 47514 35765 110505937
Back pain 71.72 23.12 35 47562 370961 110170741
Aortic stenosis 71.57 23.12 53 47544 13006 110528696
Respiratory depression 71.07 23.12 78 47519 31923 110509779
Anion gap 70.57 23.12 28 47569 1957 110539745
Vitamin B1 decreased 70.36 23.12 23 47574 916 110540786
Shock haemorrhagic 68.62 23.12 71 47526 27176 110514526
Cardiac output increased 66.90 23.12 20 47577 591 110541111
Confusional state 66.78 23.12 62 47535 468618 110073084
Contraindicated product administered 66.56 23.12 13 47584 248254 110293448
Emotional distress 66.38 23.12 89 47508 44758 110496944
Haemothorax 66.31 23.12 40 47557 6991 110534711
Blood creatinine increased 66.31 23.12 201 47396 182688 110359014
Dyspepsia 66.16 23.12 4 47593 190961 110350741
Thrombosis 65.94 23.12 145 47452 108517 110433185
Memory impairment 65.68 23.12 5 47592 196939 110344763
Hypersensitivity 65.56 23.12 47 47550 403951 110137751
Feeling abnormal 65.07 23.12 3 47594 180708 110360994
Chest pain 64.81 23.12 41 47556 376334 110165368
Gout 64.24 23.12 79 47518 36487 110505215
Diabetes mellitus 64.18 23.12 136 47461 99245 110442457
Arteriospasm coronary 63.96 23.12 43 47554 9057 110532645
Impaired healing 62.85 23.12 6 47591 196711 110344991
Anaphylactic shock 62.52 23.12 93 47504 51453 110490249
Amylase increased 62.38 23.12 48 47549 12471 110529231
Bronchopulmonary aspergillosis allergic 62.08 23.12 41 47556 8385 110533317
Nausea 61.80 23.12 298 47299 1235392 109306310
Injection site pain 60.82 23.12 4 47593 177918 110363784
Muscular weakness 60.63 23.12 16 47581 248452 110293250
Infection 60.27 23.12 41 47556 362159 110179543
Premature delivery 60.08 23.12 70 47527 30562 110511140
Cardiomyopathy 59.81 23.12 73 47524 33452 110508250
Wrong product administered 58.99 23.12 44 47553 10916 110530786
Hyperdynamic left ventricle 58.90 23.12 18 47579 574 110541128
Ischaemic hepatitis 58.73 23.12 32 47565 4616 110537086
Dyspnoea 58.23 23.12 262 47335 1106610 109435092
Blood test abnormal 57.26 23.12 66 47531 28488 110513214
Chronic obstructive pulmonary disease 56.69 23.12 137 47460 109021 110432681
Methaemoglobinaemia 56.61 23.12 40 47557 9128 110532574
Ill-defined disorder 55.21 23.12 3 47594 156850 110384852
Total lung capacity decreased 53.34 23.12 35 47562 7079 110534623
Loss of personal independence in daily activities 52.40 23.12 3 47594 150017 110391685
Ischaemia 52.34 23.12 38 47559 9045 110532657
Systolic dysfunction 51.94 23.12 29 47568 4386 110537316
Bacteroides infection 51.03 23.12 25 47572 2894 110538808
Brain death 50.91 23.12 33 47564 6540 110535162
Atrioventricular block first degree 50.90 23.12 45 47552 14180 110527522
Transaminases increased 50.86 23.12 95 47502 63295 110478407
Cardiotoxicity 49.91 23.12 48 47549 16833 110524869
Cholestasis 49.66 23.12 95 47502 64423 110477279
Bronchitis 49.61 23.12 5 47592 157027 110384675
Neuropathy peripheral 48.87 23.12 9 47588 179268 110362434
Suicide attempt 48.67 23.12 125 47472 103269 110438433
Myocardial calcification 48.64 23.12 13 47584 253 110541449
Inspiratory capacity decreased 47.70 23.12 23 47574 2572 110539130
Cardio-respiratory arrest 47.43 23.12 133 47464 115703 110425999
Influenza 47.16 23.12 8 47589 169093 110372609
Pulse absent 47.09 23.12 39 47558 11253 110530449
Nervous system disorder 47.02 23.12 63 47534 31658 110510044
Ventricular arrhythmia 46.63 23.12 37 47560 10050 110531652
Product dose omission issue 46.48 23.12 42 47555 321740 110219962
Wheezing 46.46 23.12 26 47571 255204 110286498
Leukocytosis 46.12 23.12 83 47514 53745 110487957
Lung opacity 46.02 23.12 39 47558 11613 110530089
Pulmonary embolism 45.53 23.12 198 47399 214276 110327426
Hyperkalaemia 44.37 23.12 144 47453 135652 110406050
Blood pressure decreased 44.07 23.12 129 47468 114962 110426740
Electrocardiogram ST segment depression 43.73 23.12 28 47569 5433 110536269
General physical health deterioration 43.69 23.12 323 47274 424972 110116730
Vitamin B1 increased 43.59 23.12 11 47586 169 110541533
Oropharyngeal pain 43.54 23.12 4 47593 135272 110406430
Hepatic enzyme increased 42.74 23.12 45 47552 320847 110220855
Cardiovascular insufficiency 42.55 23.12 23 47574 3265 110538437
Angiopathy 42.47 23.12 33 47564 8697 110533005
Dehydration 42.16 23.12 35 47562 279476 110262226
Depression 41.71 23.12 45 47552 317290 110224412
Anion gap increased 41.70 23.12 25 47572 4319 110537383
Torsade de pointes 41.60 23.12 50 47547 22550 110519152
Product use in unapproved indication 41.08 23.12 331 47266 447046 110094656
Erythema 40.95 23.12 39 47558 291408 110250294
Acute lung injury 40.66 23.12 22 47575 3129 110538573
Electrocardiogram T wave alternans 40.30 23.12 10 47587 143 110541559
Respiratory gas exchange disorder 40.27 23.12 15 47582 883 110540819
Myalgia 39.97 23.12 23 47574 222358 110319344
Urticaria 39.96 23.12 47 47550 318810 110222892
Acute respiratory failure 39.65 23.12 95 47502 75165 110466537
Palpitations 39.31 23.12 10 47587 159202 110382500
Hospitalisation 39.17 23.12 7 47590 142486 110399216
Chest discomfort 39.11 23.12 13 47584 173835 110367867
Urinary tract infection 38.88 23.12 50 47547 326232 110215470
Respiratory acidosis 38.42 23.12 38 47559 13788 110527914
Aspiration 38.34 23.12 56 47541 30477 110511225
Pneumothorax 37.64 23.12 60 47537 35225 110506477
Ulcer 37.60 23.12 67 47530 43049 110498653
COVID-19 treatment 37.38 23.12 12 47585 451 110541251
Renal tubular necrosis 36.98 23.12 55 47542 30420 110511282
Acute generalised exanthematous pustulosis 36.76 23.12 46 47551 21618 110520084
Systemic candida 36.58 23.12 32 47565 9942 110531760
Gangrene 36.58 23.12 40 47557 16301 110525401
Cardiovascular disorder 36.52 23.12 47 47550 22713 110518989
Hepatic failure 36.46 23.12 87 47510 68652 110473050
Blood pressure increased 35.80 23.12 35 47562 258338 110283364
Product use issue 34.88 23.12 50 47547 311645 110230057
Reversible cerebral vasoconstriction syndrome 34.67 23.12 23 47574 4738 110536964
Mydriasis 34.37 23.12 45 47552 22112 110519590
Burkholderia test positive 33.87 23.12 12 47585 612 110541090
Vasoconstriction 33.77 23.12 14 47583 1096 110540606
Somnolence 33.48 23.12 231 47366 297218 110244484
Completed suicide 33.39 23.12 33 47564 242348 110299354
Alanine aminotransferase increased 33.31 23.12 162 47435 183611 110358091
Inflammation 33.31 23.12 21 47576 193217 110348485
Acid base balance abnormal 32.91 23.12 11 47586 470 110541232
Herpes zoster 32.84 23.12 4 47593 108375 110433327
Inappropriate schedule of product administration 32.60 23.12 24 47573 203613 110338089
Dry skin 32.55 23.12 4 47593 107649 110434053
Thrombocytopenia 32.47 23.12 259 47338 348626 110193076
Depressed level of consciousness 32.21 23.12 114 47483 112164 110429538
Visual impairment 32.14 23.12 9 47588 134419 110407283
Hypovolaemia 32.05 23.12 43 47554 21631 110520071
Amnesia 31.67 23.12 4 47593 105404 110436298
Balance disorder 31.45 23.12 6 47591 116554 110425148
Necrosis 31.05 23.12 31 47566 11375 110530327
Blood creatine phosphokinase increased 30.99 23.12 85 47512 72992 110468710
Electrocardiogram abnormal 30.59 23.12 39 47558 18670 110523032
Diabetic macroangiopathy 30.52 23.12 8 47589 144 110541558
Therapeutic product effect incomplete 30.22 23.12 31 47566 223774 110317928
Pleuritic pain 30.19 23.12 36 47561 16104 110525598
Malignant neoplasm progression 30.04 23.12 19 47578 174548 110367154
Systolic anterior motion of mitral valve 29.90 23.12 7 47590 77 110541625
Benign prostatic hyperplasia 29.80 23.12 38 47559 18196 110523506
Vasodilatation 29.49 23.12 19 47578 3725 110537977
Coma scale abnormal 29.41 23.12 28 47569 9698 110532004
Immune effector cell-associated neurotoxicity syndrome 29.35 23.12 34 47563 14748 110526954
Gastrooesophageal reflux disease 29.08 23.12 21 47576 179955 110361747
Swelling face 29.00 23.12 3 47594 92318 110449384
Blood lactate dehydrogenase increased 28.99 23.12 61 47536 44273 110497429
Neutropenia 28.91 23.12 75 47522 374545 110167157
Adverse event 28.52 23.12 6 47591 108803 110432899
Pyrexia 28.26 23.12 249 47348 898016 109643686
Wound infection 28.17 23.12 4 47593 96461 110445241
Myocardial stunning 28.06 23.12 9 47588 337 110541365
Gastrointestinal necrosis 27.83 23.12 23 47574 6617 110535085
Blood lactic acid increased 27.49 23.12 34 47563 15787 110525915
Influenza like illness 27.44 23.12 3 47594 88409 110453293
Pleural effusion 26.90 23.12 149 47448 177560 110364142
Aspartate aminotransferase increased 26.87 23.12 138 47459 159798 110381904
Supraventricular tachycardia 26.70 23.12 42 47555 24380 110517322
Micturition urgency 26.56 23.12 37 47560 19283 110522419
Sinus tachycardia 26.56 23.12 59 47538 44434 110497268
Hyperthermia malignant 26.39 23.12 18 47579 3882 110537820
Unmasking of previously unidentified disease 26.23 23.12 16 47581 2852 110538850
Haemorrhage 26.16 23.12 103 47494 106589 110435113
Right ventricular failure 26.14 23.12 43 47554 25911 110515791
Cardiac tamponade 25.87 23.12 28 47569 11279 110530423
Hypoxic-ischaemic encephalopathy 25.86 23.12 25 47572 8822 110532880
Hypothermia 25.72 23.12 43 47554 26259 110515443
Procedural hypotension 25.57 23.12 15 47582 2490 110539212
Maternal exposure during delivery 25.42 23.12 17 47580 3548 110538154
Intentional product misuse 25.42 23.12 119 47478 132785 110408917
Hyperthermia 25.25 23.12 38 47559 21234 110520468
Respiratory distress 25.22 23.12 76 47521 68798 110472904
Pseudomonas infection 25.21 23.12 44 47553 27809 110513893
Rectal haemorrhage 25.19 23.12 10 47587 119823 110421879
Treatment failure 25.02 23.12 51 47546 277183 110264519
Illness 24.98 23.12 3 47594 82168 110459534
Gastrointestinal disorder 24.96 23.12 41 47556 241911 110299791
Dyspnoea exertional 24.81 23.12 7 47590 104053 110437649
Pneumatosis intestinalis 24.74 23.12 24 47573 8505 110533197
Hypoperfusion 24.71 23.12 16 47581 3165 110538537
Sinus bradycardia 24.67 23.12 45 47552 29438 110512264
Cholangiolitis 24.65 23.12 5 47592 26 110541676
Obesity 24.59 23.12 9 47588 113342 110428360
Blood potassium increased 24.41 23.12 48 47549 33201 110508501
Asthma 24.37 23.12 44 47553 250247 110291455
Brain oedema 24.19 23.12 46 47551 31052 110510650
Hypertransaminasaemia 24.18 23.12 40 47557 24215 110517487
Catheter site haemorrhage 23.88 23.12 20 47577 5860 110535842
Dysphagia 23.44 23.12 19 47578 153581 110388121
C-reactive protein increased 23.35 23.12 36 47561 217883 110323819
Flushing 23.26 23.12 8 47589 104728 110436974

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA03 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA CS M0003647 Catecholamines
FDA EPC N0000175570 Catecholamine
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D014662 Vasoconstrictor Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
CHEBI has role CHEBI:76967 human xenobiotic metabolite

Related Drugs by ATC class:

C01CA Adrenergic and dopaminergic agents 25 drugs
amezinium metilsulfatearbutaminecafedrinedimetofrinedobutaminedopaminedopexaminedroxidopaephedrineepinephrineetilefrinefenoldopam show all 25 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bronchiectasis indication 12295008 DOID:9563
Bronchitis indication 32398004 DOID:6132
Low blood pressure indication 45007003
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Asthma management indication 406162001
Acute exacerbation of asthma indication 708038006
Hypovolemia contraindication 28560003
Hypercapnia contraindication 29596007
Hypertensive disorder contraindication 38341003 DOID:10763
Hypoxia contraindication 389086002
Thrombosis contraindication 439127006
Occlusive Vascular Disease contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.41 acidic
pKa2 12.03 acidic
pKa3 12.63 acidic
pKa4 8.83 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 10226436 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 10420735 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 11413259 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 10226436 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 10420735 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 11413259 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 10226436 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 10420735 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE LONG GROVE PHARMS N214628 Oct. 6, 2022 RX SOLUTION INTRAVENOUS 11413259 Jan. 30, 2038 INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE BAXTER HLTHCARE CORP N214313 Nov. 21, 2023 RX SOLUTION INTRAVENOUS 12097170 March 8, 2041 TO RESTORE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSIVE STATES
EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE BAXTER HLTHCARE CORP N214313 Jan. 15, 2021 RX SOLUTION INTRAVENOUS 12097170 March 8, 2041 TO RESTORE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSIVE STATES
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE BAXTER HLTHCARE CORP N214313 Jan. 15, 2021 RX SOLUTION INTRAVENOUS 12097170 March 8, 2041 TO RESTORE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSIVE STATES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-1B adrenergic receptor GPCR AGONIST Ki 4.69 CHEMBL CHEMBL
Alpha-1A adrenergic receptor GPCR AGONIST Ki 5.82 CHEMBL CHEMBL
Beta-1 adrenergic receptor GPCR AGONIST Ki 6 IUPHAR CHEMBL
Beta-2 adrenergic receptor GPCR AGONIST Kd 5.40 CHEMBL CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST Ki 7.20 CHEMBL CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST Ki 7.18 CHEMBL CHEMBL
Alpha-1D adrenergic receptor GPCR AGONIST Ki 7.40 IUPHAR CHEMBL
D(1A) dopamine receptor GPCR Kd 4.30 CHEMBL
D(2) dopamine receptor GPCR Ki 5.89 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.48 PDSP
Beta-3 adrenergic receptor GPCR Ki 5.37 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.07 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.11 CHEMBL
Mu-type opioid receptor GPCR Ki 4.85 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.22 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 6.90 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.30 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 6.35 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 6.58 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 8.32 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 6.41 CHEMBL
Adrenergic receptor alpha GPCR IC50 7.80 CHEMBL
Adrenergic receptor beta GPCR IC50 6 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 6.19 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 6.40 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.24 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.38 CHEMBL

External reference:

IDSource
4019859 VUID
N0000147945 NUI
D00076 KEGG_DRUG
108341-18-0 SECONDARY_CAS_RN
4018242 VANDF
4019859 VANDF
C0028351 UMLSCUI
CHEBI:18357 CHEBI
LT4 PDB_CHEM_ID
CHEMBL1437 ChEMBL_ID
DB00368 DRUGBANK_ID
CHEMBL1434513 ChEMBL_ID
D009638 MESH_DESCRIPTOR_UI
439260 PUBCHEM_CID
7508 RXNORM
2706 MMSL
333906 MMSL
35060 MMSL
5186 MMSL
NOCODE MMSL
d00323 MMSL
001777 NDDF
004718 NDDF
111130009 SNOMEDCT_US
45555007 SNOMEDCT_US
77673009 SNOMEDCT_US
484 IUPHAR_LIGAND_ID
IFY5PE3ZRW UNII
IFY5PE3ZRW INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9318 INJECTION 1 mg INTRAVENOUS ANDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0040 INJECTION, SOLUTION 4 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0042 INJECTION, SOLUTION 8 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0108 INJECTION, SOLUTION 8 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0112 INJECTION, SOLUTION 4 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0116 INJECTION, SOLUTION 16 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0128 INJECTION, SOLUTION 16 mg INTRAVENOUS NDA 24 sections
LEVOPHED HUMAN PRESCRIPTION DRUG LABEL 1 0409-0161 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 25 sections
LEVOPHED HUMAN PRESCRIPTION DRUG LABEL 1 0409-1443 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 25 sections
LEVOPHED HUMAN PRESCRIPTION DRUG LABEL 1 0409-3375 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 25 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3755 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 25021-316 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 25 sections
Norepinephrine bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 31722-372 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 42023-245 INJECTION, SOLUTION 4 mg INTRAVENOUS NDA 21 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 42023-246 INJECTION, SOLUTION 8 mg INTRAVENOUS NDA 21 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 42023-247 INJECTION, SOLUTION 16 mg INTRAVENOUS NDA 21 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 43066-997 INJECTION 1 mg INTRAVENOUS ANDA 24 sections
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-640 INJECTION, SOLUTION 0.02 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-640 INJECTION, SOLUTION 0.02 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-641 INJECTION, SOLUTION 0.03 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-641 INJECTION, SOLUTION 0.03 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-642 INJECTION, SOLUTION 0.06 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-642 INJECTION, SOLUTION 0.06 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-643 INJECTION, SOLUTION 0.13 mg INTRAVENOUS NDA 24 sections
NOREPINEPHRINE BITARTRATE Human Prescription Drug Label 1 47335-615 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 24 sections
LEVOPHED(R) NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1315 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS NDA 12 sections
NOREPINEPHRINE BITARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1528 INJECTION 1 mg INTRAVENOUS ANDA 16 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 51991-983 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 25 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 51991-983 INJECTION, SOLUTION, CONCENTRATE 1 mg INTRAVENOUS ANDA 25 sections
Norepinephrine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 1 52533-164 INJECTION, SOLUTION 64 ug INTRAVENOUS unapproved drug other 7 sections